In 2024, around 16 percent of adults between the ages of 20 and 79 had diabetes in Turkey. Other selected countries with a high prevalence of diabetes that year included Mexico, the United States, and Portugal. Diabetes is a metabolic disease that causes high blood sugar levels. Diabetes worldwide In 2024, an estimated 11 percent of the global adult population had diabetes. In concrete numbers, there were about 589 million diabetic adults (20-79 years) worldwide in 2024, and this total is predicted to grow to approximately 852.5 million by the year 2050. Spending per patient The country that spent the most on patients with diabetes in 2024 was Switzerland. At that time, providing for a diabetic patient in Switzerland cost an average of over 12 thousand U.S. dollars. The United States stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. Bangladesh had the lowest annual diabetes-related health expenditures per person, with just 74 U.S. dollars.

In 2024, Bangladesh was the country with the lowest spending per patient with diabetes in the world, with average annual expenditures amounting to just 74 U.S. dollars that year. Other countries with low diabetes spending per diabetic person included Pakistan, the Democratic Republic of the Congo, and Madagascar. Worldwide cost of diabetes The cost of diabetes in 2024 was by far the highest in North America and the Caribbean: the average cost per diabetic patient was approximately 7,812 U.S. dollars for that region. With less than half that, Europe had the second-highest diabetes costs with roughly 2,951 U.S. dollars. Diabetes in 2050 In 2024, it was estimated that around 589 million people worldwide had diabetes. By 2050, this number is forecast to reach almost 853 million. That would mean that in 2050 around 13 percent of the world population would be suffering from diabetes. In 2024, an estimated 11 percent of the world population had diabetes.

Portugal had the highest prevalence of diabetes in Europe among their adult population with **** percent living with diabetes, as of 2024, Croatia followed with the second-highest share at **** percent. Conversely, Ireland was the country with the lowest prevalence of diabetes in Europe at *** percent. Diabetes-related deaths The highest number of diabetes-related deaths in Europe, at almost ******, was recorded in Germany in 2024. Italy and France followed, with roughly *******and ****** deaths, respectively. Diabetes risk factors in Europe One of the major contributing factors to type 2 diabetes is being overweight or obese. As of 2022, Greece had the highest share of overweight population across Europe, with *****percent. The lack of sports and exercise is also another risk factor. As of 2022, Portugal was the European country with the highest share of people never exercising or engaging in sports, with ** percent.

The average for 2021 based on 27 countries was 6.24 percent. The highest value was in Spain: 10.3 percent and the lowest value was in Ireland: 3 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

China is the country with the highest number of diabetics worldwide, with around *** million people suffering from the disease. By the year 2050, it is predicted that China will have around *** million people with diabetes. Death from diabetes Diabetes is one of the leading causes of death worldwide, accounting for **** million deaths in 2021. Diabetes at least doubles one’s chance of dying prematurely, and many places in the world lack appropriate treatment options. The highest number of deaths from diabetes comes from the Western Pacific, where around *** million people died from the disease in 2024. Obesity One of the biggest risk factors for developing diabetes is being overweight or obese. Rates of obesity have increased in recent years in many countries around the world. In the United States, for example, it is estimated that around ** percent of the adult population was obese in 2023, compared to ** percent of the population in 2011.

The average for 2021 based on 20 countries was 8.73 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Ecuador: 4.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

In 2024, more than ** percent of the population aged 20 to 79 years in Pakistan had diabetes. In comparison, Timor-Leste had the lowest prevalence of diabetic people aged 20 to 79 across the Asia-Pacific region that year, approximately *** percent.

In 2021, Tanzania had the highest prevalence of diabetes in East Africa, with **** percent of its population living with diabetes. The Seychelles followed with the second-highest share at *** percent. Conversely, Kenya was the country with the lowest prevalence of diabetes in the region at ***** percent.

This statistic shows the top 10 countries based on number of new cases of type 1 diabetes per 100,000 children aged 0 to 14 years, in 2021. Finland had the highest rate with 52.2 new cases per 100,000 children per year.

BackgroundThe prevalence of diabetes is increasing rapidly in low- and middle-income countries (LMICs), urgently requiring detailed evidence to guide the response of health systems to this epidemic. In an effort to understand at what step in the diabetes care continuum individuals are lost to care, and how this varies between countries and population groups, this study examined health system performance for diabetes among adults in 28 LMICs using a cascade of care approach.Methods and findingsWe pooled individual participant data from nationally representative surveys done between 2008 and 2016 in 28 LMICs. Diabetes was defined as fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl), random plasma glucose ≥ 11.1 mmol/l (200 mg/dl), HbA1c ≥ 6.5%, or reporting to be taking medication for diabetes. Stages of the care cascade were as follows: tested, diagnosed, lifestyle advice and/or medication given (“treated”), and controlled (HbA1c < 8.0% or equivalent). We stratified cascades of care by country, geographic region, World Bank income group, and individual-level characteristics (age, sex, educational attainment, household wealth quintile, and body mass index [BMI]). We then used logistic regression models with country-level fixed effects to evaluate predictors of (1) testing, (2) treatment, and (3) control. The final sample included 847,413 adults in 28 LMICs (8 low income, 9 lower-middle income, 11 upper-middle income). Survey sample size ranged from 824 in Guyana to 750,451 in India. The prevalence of diabetes was 8.8% (95% CI: 8.2%–9.5%), and the prevalence of undiagnosed diabetes was 4.8% (95% CI: 4.5%–5.2%). Health system performance for management of diabetes showed large losses to care at the stage of being tested, and low rates of diabetes control. Total unmet need for diabetes care (defined as the sum of those not tested, tested but undiagnosed, diagnosed but untreated, and treated but with diabetes not controlled) was 77.0% (95% CI: 74.9%–78.9%). Performance along the care cascade was significantly better in upper-middle income countries, but across all World Bank income groups, only half of participants with diabetes who were tested achieved diabetes control. Greater age, educational attainment, and BMI were associated with higher odds of being tested, being treated, and achieving control. The limitations of this study included the use of a single glucose measurement to assess diabetes, differences in the approach to wealth measurement across surveys, and variation in the date of the surveys.ConclusionsThe study uncovered poor management of diabetes along the care cascade, indicating large unmet need for diabetes care across 28 LMICs. Performance across the care cascade varied by World Bank income group and individual-level characteristics, particularly age, educational attainment, and BMI. This policy-relevant analysis can inform country-specific interventions and offers a baseline by which future progress can be measured.

In 2021, South Africa had the highest prevalence of diabetes in Southern Africa, with **** percent of its population living with diabetes. Botswana followed with the second-highest share at *** percent. Conversely, Zimbabwe was the country with the lowest prevalence of diabetes in the region at *** percent.

Type-1 Diabetes Treatment Market Outlook

The global Type-1 Diabetes Treatment market size is projected to grow significantly from USD 7.2 billion in 2023 to an estimated USD 12.6 billion by 2032, at a compound annual growth rate (CAGR) of 6.5%. The market growth is primarily driven by the rising prevalence of Type-1 diabetes worldwide, coupled with advancements in medical technology and treatment methods. Additionally, increasing awareness and early diagnosis of the disease have been pivotal in expanding the market's reach.

One of the major growth factors for the Type-1 Diabetes Treatment market is the continuous development and approval of innovative insulin delivery systems. Technologies such as insulin pumps, continuous glucose monitors, and artificial pancreas systems are revolutionizing diabetes care by offering more precise and convenient methods for managing blood sugar levels. These advancements not only improve the quality of life for patients but also reduce long-term complications associated with poor blood glucose control, thereby driving market expansion.

Another significant growth driver is the increasing investment in research and development by pharmaceutical companies. Efforts to discover new treatment modalities, including non-insulin therapies and regenerative medicine approaches like pancreas and islet cell transplantation, are creating new opportunities within the market. Additionally, collaborations between academic institutions and biotech firms are accelerating the pace of innovation, bringing novel therapies closer to commercial availability.

The market is also supported by favorable government initiatives and policies aimed at improving diabetes care. Many countries are implementing national diabetes programs that include guidelines for early diagnosis, comprehensive care plans, and subsidies for treatment costs. These programs are essential in increasing access to effective treatments, particularly in low and middle-income countries where the burden of diabetes is rising rapidly.

In recent years, Diabetes Stem Cell Therapy has emerged as a promising area of research in the treatment of Type-1 diabetes. This innovative approach involves the use of stem cells to regenerate insulin-producing beta cells in the pancreas, potentially offering a more permanent solution to insulin dependency. Researchers are exploring various sources of stem cells, including embryonic stem cells and induced pluripotent stem cells, to develop effective therapies. The ultimate goal is to restore the body's ability to produce insulin naturally, thereby reducing or eliminating the need for external insulin administration. While still in the experimental stages, early clinical trials have shown encouraging results, paving the way for future advancements in this field.

Regionally, North America dominates the Type-1 Diabetes Treatment market, accounting for the largest share due to high healthcare expenditure, advanced healthcare infrastructure, and significant investment in diabetes research. Europe follows closely, with a strong focus on improving healthcare outcomes and increasing awareness about diabetes management. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the rising prevalence of diabetes, improving healthcare infrastructure, and increasing government initiatives to enhance diabetes care. Latin America and the Middle East & Africa also show promising growth potential, although these markets are currently smaller in size compared to North America and Europe.

Insulin Therapy Analysis

Insulin therapy remains the cornerstone of Type-1 diabetes treatment, accounting for a significant share of the market. The evolution of insulin formulations, including rapid-acting, long-acting, and intermediate-acting insulins, has provided patients with more options to tailor their treatment plans to their specific needs. Innovations such as biosimilar insulins have also made treatments more accessible by offering cost-effective alternatives to branded products. Continuous advancements in insulin delivery systems, such as smart insulin pens and pumps, are further enhancing the efficacy and convenience of insulin therapy.

Recent developments in insulin therapy include the advent of ultra-rapid-acting insulins, which aim to better mimic the body's natural insulin response to meals. These insulins provide faster onset and shorter durat

The average for 2021 based on 47 countries was 5.59 percent. The highest value was in Mauritius: 22.6 percent and the lowest value was in Benin: 1.1 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

BackgroundDiabetes imposes a substantial burden globally in terms of premature mortality, morbidity, and health care costs. Estimates of economic outcomes associated with diabetes are essential inputs to policy analyses aimed at prevention and treatment of diabetes. Our objective was to estimate and compare event rates, hospital utilization, and costs associated with major diabetes-related complications in high-, middle-, and low-income countries.Methods and FindingsIncidence and history of diabetes-related complications, hospital admissions, and length of stay were recorded in 11,140 patients with type 2 diabetes participating in the Action in Diabetes and Vascular Disease (ADVANCE) study (mean age at entry 66 y). The probability of hospital utilization and number of days in hospital for major events associated with coronary disease, cerebrovascular disease, congestive heart failure, peripheral vascular disease, and nephropathy were estimated for three regions (Asia, Eastern Europe, and Established Market Economies) using multiple regression analysis. The resulting estimates of days spent in hospital were multiplied by regional estimates of the costs per hospital bed-day from the World Health Organization to compute annual acute and long-term costs associated with the different types of complications. To assist, comparability, costs are reported in international dollars (Int$), which represent a hypothetical currency that allows for the same quantities of goods or services to be purchased regardless of country, standardized on purchasing power in the United States. A cost calculator accompanying this paper enables the estimation of costs for individual countries and translation of these costs into local currency units. The probability of attending a hospital following an event was highest for heart failure (93%–96% across regions) and lowest for nephropathy (15%–26%). The average numbers of days in hospital given at least one admission were greatest for stroke (17–32 d across region) and heart failure (16–31 d) and lowest for nephropathy (12–23 d). Considering regional differences, probabilities of hospitalization were lowest in Asia and highest in Established Market Economies; on the other hand, lengths of stay were highest in Asia and lowest in Established Market Economies. Overall estimated annual hospital costs for patients with none of the specified events or event histories ranged from Int$76 in Asia to Int$296 in Established Market Economies. All complications included in this analysis led to significant increases in hospital costs; coronary events, cerebrovascular events, and heart failure were the most costly, at more than Int$1,800, Int$3,000, and Int$4,000 in Asia, Eastern Europe, and Established Market Economies, respectively.ConclusionsMajor complications of diabetes significantly increase hospital use and costs across various settings and are likely to impose a high economic burden on health care systems. Please see later in the article for the Editors' Summary

In 2024, Pakistan had the highest prevalence of diabetes worldwide, with around ** percent of the population suffering from the disease. Diabetes mellitus, or simply, diabetes, refers to a group of metabolic disorders that cause high blood sugar levels. Diabetes can be prevented and treated though exercise, maintaining normal body weight, and healthy eating, but is usually managed with insulin injections. Costs As of 2024, there were almost *** million people worldwide who had diabetes. With such a huge number of people suffering from this disease, it is no surprise that spending on diabetes can be very high. It is estimated that the United States alone spent around ***** billion U.S. dollars on diabetes health expenditure in 2024. The countries with the highest spending per patient with diabetes include Switzerland, the United States, and Norway. Death Diabetes is among the leading ten causes of death worldwide, accounting for around **** million deaths in 2021. Complications resulting from diabetes include chronic kidney disease, stroke, and cardiovascular disease. The risk of early death is at least doubled among those with diabetes. The Western Pacific reports the highest number of deaths from diabetes, followed by North America and the Caribbean.

IntroductionType 2 diabetes is increasing worldwide, and the trend is also observed in Sweden. In Malmö, the third largest city in Sweden, the prevalence has doubled. Populations with lower socioeconomic status have a higher prevalence and poorer outcomes, making preventive interventions targeting these groups increasingly important.ObjectiveTo investigate the types of interventions that have been tested and reported regarding the prevention of type 2 diabetes targeting low socioeconomic populations and are applicable in a high-income country.MethodsBased on a systematic search strategy developed using the People, Concept, and Context model, the databases CINAHL, PubMed, and Web of Science were searched in January 2024 and updated in December 2024, and EMBASE was searched in May 2025. A flowchart of the screening process has been created. From the selected studies, data were extracted, charted, and the findings were compiled in a narrative form.ResultsSeventeen studies were included, 12 were conducted in the United States and five in Europe. Most used culturally adapted diabetes prevention programs, and a higher proportion of participants were women. Key features included flexibility in attendance and format, development through a community-based participatory approach, gender-specific groups, and the involvement of significant others. Increases of physical activity proved challenging within broader lifestyle interventions. Screening interventions were conducted in community and healthcare facility settings, as well as through a school-and community-based program. Challenges with enrollment and retention were commonly reported.ConclusionThere is a need for more interventions in the European context and for interventions to engage more men with strategies such as male peer coaches and community screening in locations frequented by men. Longer time frames and sustained engagement strategies are necessary to reach and retain groups with low socioeconomic status in preventive type 2 diabetes interventions.

The average for 2021 based on 13 countries was 15.77 percent. The highest value was in New Caledonia: 23.4 percent and the lowest value was in New Zealand: 6.2 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

As of 2021, the age-adjusted diabetes prevalence in Kuwait was **** percent. The majority of countries in the Middle East and North Africa had age-adjusted rates of above ** percent. During the same period, Yemen had the lowest rate at *** percent.

Baseline characteristics of participants with diabetes (n = 40,701) in population-based surveys conducted in 28 low- and middle-income countries between 2008 and 2016.

In 2021, it was estimated that China had about 141 million diabetics aged from 20 to 79 years, which was the highest number of any country. The figure would very likely climb to 174 million by 2045. Diabetes is one of the leading death causes across the globe.

An overview of diabetes

Diabetes mellitus, commonly known as diabetes, is an incurable chronic health condition in which dangerously high levels of glucose flood the body due to the lack of insulin production (type 1 diabetes) or the body’s inability to use insulin to regulate blood sugar levels (type 2 and gestational diabetes). Globally, the number of people suffering from this chronic disease amounted to 537 million in 2021. The largest number of diabetics were from China, followed by India and Pakistan in that year. In terms of diabetes prevalence, French Polynesia, Mauritius, and Kuwait had the highest rates. With regard to diabetes-related health expenditure, China alone spent over half of the amount spent by the entire Western Pacific region.

Key figures of diabetes in China

Back in the 1980s, less than one percent of the Chinese population was said to have diabetes. In the recent decade, the prevalence rate has jumped to an alarming level, and about one in five of all adult diabetes sufferers worldwide were in China. Records from 2021 show that most of such patients in the country fell within the age group of 20 to 79 years - mainly type 2 diabetes. Some experts point out the nation’s economic growth coupled with unhealthy diets and reduced physical activity as major risk factors which cause type 2 diabetes. It is worth noting that the awareness and control rates of diabetes were relatively low in China compared with the situations in other strong economies.